Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)

Next Previous
Trial Profile

A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ANITSCHKOW
  • Sponsors Amgen

Most Recent Events

  • 08 Apr 2020 Results (n=32) assessing gene expression profile of circulating monocytes of healthy individuals and CVD patients, both with elevated Lp(a) in two studies (AKCEA-APO(a)-LRx study (NCT03070782) and the ANITSCHKOW study (NCT02729025)), published in the European Heart Journal.
  • 18 Dec 2018 Primary endpoint (Effect of Repatha (Evolocumab) on Lp(a), as measured by percent change from baseline at week 16 in target-to-background ratio of an index vessel by FDG-PET/CT in subjects with baseline Lp(a)50mg/dL and Low-density lipoprotein-cholesterol100mg/dL) has not been met as per results published in the European Heart Journal
  • 18 Dec 2018 Results published in the European Heart Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top